Gain Therapeutics Inc (NASDAQ: GANX) is -10.57% lower on its value in year-to-date trading and has touched a low of $0.89 and a high of $5.33 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The GANX stock was last observed hovering at around $2.40 in the last trading session, with the day’s gains setting it 0.52%.
Currently trading at $2.92, the stock is 52.98% and 94.47% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.2 million and changing 21.67% at the moment leaves the stock 11.98% off its SMA200. GANX registered -10.43% loss for a year compared to 6-month loss of -8.18%. The firm has a 50-day simple moving average (SMA 50) of $1.46312 and a 200-day simple moving average (SMA200) of $2.6094.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 95.32% gain in the last 1 month and extending the period to 3 months gives it a 139.34%, and is 43.14% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 15.86% over the week and 13.49% over the month.
Gain Therapeutics Inc (GANX) has around 32 employees, a market worth around $74.58M and $0.00M in sales. Distance from 52-week low is 228.09% and -45.22% from its 52-week high. The company has generated returns on investments over the last 12 months (-175.69%).
The EPS is expected to grow by 39.42% this year
32.0 institutions hold shares in Gain Therapeutics Inc (GANX), with institutional investors hold 12.56% of the company’s shares. The shares outstanding are 25.54M, and float is at 24.23M with Short Float at 2.70%. Institutions hold 11.92% of the Float.
The top institutional shareholder in the company is TIMELO INVESTMENT MANAGEMENT INC. with over 0.61 million shares valued at $0.77 million. The investor’s holdings represent 3.3666 of the GANX Shares outstanding. As of 2024-06-30, the second largest holder is DME CAPITAL MANAGEMENT, LP with 0.57 million shares valued at $0.72 million to account for 3.1488 of the shares outstanding. The other top investors are ALYESKA INVESTMENT GROUP, L.P. which holds 0.45 million shares representing 2.5029 and valued at over $0.58 million, while HOHIMER WEALTH MANAGEMENT, LLC holds 1.8355 of the shares totaling 0.33 million with a market value of $0.42 million.
Gain Therapeutics Inc (GANX) Insider Activity
The most recent transaction is an insider purchase by Mack Gene, the company’s CFO and Interim CEO. SEC filings show that Mack Gene bought 14,400 shares of the company’s common stock on Aug 09 ’24 at a price of $1.01 per share for a total of $14544.0. Following the purchase, the insider now owns 14400.0 shares.
Gain Therapeutics Inc disclosed in a document filed with the SEC on Aug 09 ’24 that Islam Khalid (Executive Chairman) bought a total of 50,000 shares of the company’s common stock. The trade occurred on Aug 09 ’24 and was made at $1.00 per share for $49940.0. Following the transaction, the insider now directly holds 50000.0 shares of the GANX stock.
Still, SEC filings show that on Jul 01 ’24, RICHMAN ERIC I (Director) acquired 17,000 shares at an average price of $1.22 for $20670.0. The insider now directly holds 289,629 shares of Gain Therapeutics Inc (GANX).
